Clinical Trials Logo

Clinical Trial Summary

The primary purpose of this study is to measure the correlation between baseline expression of aging biomarkers, SenesceTest in blood of organ donor and renal graft function. This pilot study will study patients who are undergoing renal transplantation with organs from extended criteria donors, standard criteria donors or donation after cardiac death and compare ability of SenesceTest to predict renal graft function immediately after the transplant and at 1 year followup.


Clinical Trial Description

Presently, donated organs are ranked amongst each other based on a formula for Kidney Donor Patient Index (KDPI; a variation of Donor Risk index) 8 which includes donor demographics and clinical history but no molecular markers of kidney function other than serum creatinine. Using KDPI assessment, nearly all ECD kidneys fall into the high-risk category. And while ECD kidneys are associated with higher risk of graft failure, studies note a wide variability in ECD organ quality and the associated graft survival (half-life graft survival 4.5-7.9 years), suggesting that current models of assessing organ quality are inadequate. Furthermore, prior to even being assigned a KDPI, over 37% of all kidneys and over 50% of ECD kidneys are discarded based on biopsy findings. However, recent studies called into question the reliance on procurement kidney biopsy reports in making acceptance decisions by demonstrating significant overlap in the biopsy findings between discarded and transplanted kidneys. The use of ECD kidneys is becoming more widespread and, according to a recent report, 70% adults >65yo and 50% adults between 50 and 64 yo are willing to accept an ECD kidney. Therefore, new methodology for assessment of graft viability would increase transplantation rates particularly for organs from older or expanded criteria donors, shorten patient's time on wait list (currently 45 months average 50) and improve their outcomes by taking them off dialysis sooner.

Here, we propose a new approach—using molecular age markers (collectively referred to as SenesceTest) to predict kidney graft function. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT02335333
Study type Observational
Source HealthSpan Dx
Contact
Status Completed
Phase N/A
Start date January 2015
Completion date December 2015

See also
  Status Clinical Trial Phase
Withdrawn NCT02312115 - Delayed Renal Allograft Function and Furosemide Treatment Phase 2
Completed NCT02134314 - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI Phase 1/Phase 2
Completed NCT02346968 - Evaluation of CAF22 After Renal Transplantation
Completed NCT01794663 - Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function Phase 2
Completed NCT00298181 - YSPSL for Prevention of Delayed Graft Function Part A Phase 1/Phase 2
Not yet recruiting NCT05166460 - Novel Cooling Device for the Elimination of Warm Ischemia During Renal Transplantation N/A
Recruiting NCT03071536 - Furosemide Stress Test Predicting Early Graft Function in Kidney Transplantation N/A
Not yet recruiting NCT05513807 - Graft Acute Kidney Injury: Vitamin B3 to Facilitate Renal Recovery In the Early Life of a Transplant Phase 3
Recruiting NCT04005469 - Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation Phase 1/Phase 2
Completed NCT01848249 - Deceased Donor Biomarkers and Recipient Outcomes
Active, not recruiting NCT02474667 - Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney Phase 3
No longer available NCT02026934 - CliniMACS® CD34+ Reagent System for Expanded Access Use N/A
Terminated NCT00217152 - A Kidney Transplant Study to Look at the Effects of Taking Fixed Doses of CellCept Versus Taking Doses of CellCept Based on the Concentration of CellCept in the Blood When Taking Full or Reduced Dose Calcineurin Inhibitors Phase 4
Recruiting NCT05430620 - Intermittent Versus Continuous Surface O2 During HMP of DCD Kidneys Phase 3
Completed NCT03864926 - Envarsus in Delayed Graft Function (E-DGF) Phase 4
Recruiting NCT06367205 - Norepinephrine Infusion Combined With Goal-directed Fluid Therapy in Patients Undergoing Kidney Transplantations N/A
Completed NCT02610296 - QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant Phase 3
Active, not recruiting NCT02568696 - Intra-graft Coagulation Events in Clinical Renal Transplantation and Delayed Graft Function
Recruiting NCT01837043 - Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function Phase 2
Terminated NCT01878786 - A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys Phase 2/Phase 3